---
title: "Vijaypd Ceutical Ltd (VIJAYPD) — Share Price, Financials & Analysis"
symbol: "VIJAYPD"
company: "Vijaypd Ceutical Ltd"
canonical: "https://tapetide.com/stocks/VIJAYPD"
isin: "INE0WL901019"
nse_symbol: "VIJAYPD"
sector: "Industrials"
industry: "Electrical Equipment"
market_cap_cr: 121.08
generated_at: "2026-09-13T20:37:33.300Z"
---

# Vijaypd Ceutical Ltd (VIJAYPD)

Canonical page: https://tapetide.com/stocks/VIJAYPD

## Company

- **NSE Symbol:** VIJAYPD
- **ISIN:** INE0WL901019
- **Sector:** Industrials
- **Industry:** Electrical Equipment
- **Macro Sector:** Industrials
- **Stock Type:** EQUITY
- **Listed Since:** 2025-10-07
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** vijaypdceutical.com

## About

Incorporated in October 1971, Vijaypd Ceutical Limited distributes pharmaceutical products and consumer goods, offering a comprehensive range of services.[1]

## Latest Price

- **Price:** ₹65
- **Change:** +3 (+4.84%)
- **Open:** ₹62
- **Day High:** ₹65
- **Day Low:** ₹62
- **Previous Close:** ₹62
- **Volume:** 4000
- **As Of:** 2026-09-11T09:56:59+00:00

## Key Fundamentals

Observed at 2026-09-11T04:45:31.596660Z.

- **Market Cap:** ₹121.08 Cr
- **Classification:** SME
- **P/E (reported):** 24.2
- **Book Value:** ₹26.88
- **Price to Book:** 2.31
- **Dividend Yield:** 0%
- **ROE:** 14.91%
- **ROCE:** 26.54%
- **Debt to Equity:** 0.64
- **Revenue (yearly):** ₹98.96 Cr
- **Net Income:** ₹4.73 Cr
- **EBITDA:** ₹4.71 Cr
- **52-Week High:** ₹114.5
- **52-Week Low:** ₹35
- **RSI (14):** 44.65

## Tapetide Score

- **Score:** 39 / 100
- **Score date:** 2026-09-04
- **Archetype:** Weak and Under Pressure
- **What it means:** Weak financials are the defining feature, and neither the valuation nor the trend reading is strong enough to offset them. Worth reading the risk flags and recent filings closely before anything else.
- **Pillar profile:** Quality: Weak · Valuation: Expensive · Momentum: Flat
- **Percentile:** 12 (of 4473 scored stocks)
- **Confidence:** 86%
- **Data coverage:** 71%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 49.75 | 9% |
| growth | 16.54 | 9% |
| momentum | 58.46 | 12% |
| ownership | 51.18 | 24% |
| quality | 35.84 | 22% |
| valuation | 29.96 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Weaknesses

- Though the company is reporting repeated profits, it is not paying out dividend
- Company might be capitalizing the interest cost
- Earnings include an other income of Rs.4.02 Cr.
- Debtor days have increased from 85.8 to 115 days.
- Working capital days have increased from 21.1 days to 64.7 days

## Growth Rates

| Metric | 1Y | 3Y |
| --- | --- | --- |
| ebitda margin growth | -42.52% | -44.54% |
| net income growth | -1.46% | 204% |
| revenue growth | -16.06% | 25% |
| roce | -55.57% | -42.01% |
| roe | -40.46% | 14.54% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
| --- | --- | --- | --- | --- |
| Sales | 50.32 | 49.91 | 51.33 | 47.62 |
| Expenses | 44.84 | 46.99 | 46.97 | 47.27 |
| Operating Profit | 5.48 | 2.92 | 4.36 | 0.35 |
| OPM % | 10.89 | 5.85 | 8.49 | 0.73 |
| Other Income | 0.01 | 0.75 | 0.32 | 3.7 |
| Interest | 1.17 | 0.98 | 1.06 | 0.53 |
| Depreciation | 0.3 | 0.31 | 0.28 | 0.34 |
| Profit before tax | 4.02 | 2.38 | 3.34 | 3.18 |
| Tax % | 26.62 | 26.05 | 27.84 | 16.67 |
| Net Profit | 2.95 | 1.76 | 2.42 | 2.64 |
| EPS in Rs | 4.21 | 1.25 | 1.73 | 1.35 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- |
| Sales | 51.09 | 59.15 | 117.09 | 98.96 |
| Expenses | 49.77 | 54.27 | 108.51 | 94.25 |
| Operating Profit | 1.32 | 4.88 | 8.58 | 4.71 |
| OPM % | 2.58 | 8.25 | 7.33 | 4.76 |
| Other Income | 1.82 | 0 | 0.78 | 4.02 |
| Interest | 2.36 | 1.76 | 2.15 | 1.59 |
| Depreciation | 0.43 | 0.35 | 0.69 | 0.62 |
| Profit before tax | 0.35 | 2.77 | 6.52 | 6.52 |
| Tax % | 48.57 | 40.43 | 26.53 | 22.39 |
| Net Profit | 0.18 | 1.65 | 4.8 | 5.06 |
| EPS in Rs | — | — | 3.42 | 2.59 |
| Dividend Payout % | 0 | 0 | 0 | 0 |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- |
| Equity Capital | 0 | 1 | 14.03 | 19.53 |
| Reserves | 4.93 | 5.59 | 18.14 | 33.01 |
| Borrowings | 25.57 | 24.45 | 21.77 | 33.67 |
| Other Liabilities | 2.37 | 2.23 | 3.21 | 11.15 |
| Total Liabilities | 32.87 | 33.27 | 57.15 | 97.36 |
| Fixed Assets | 2.73 | 2.43 | 8.44 | 8.72 |
| CWIP | 0 | 0 | 0.11 | 1.66 |
| Investments | 0.16 | 0.15 | 0.25 | 2.09 |
| Other Assets | 29.98 | 30.69 | 48.35 | 84.89 |
| Total Assets | 32.87 | 33.27 | 57.15 | 97.36 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- |
| Cash from Operating Activity | 0.3 | 2.93 | -7.89 | -7.32 |
| Cash from Investing Activity | -0.09 | 12.78 | -0.55 | -12.17 |
| Cash from Financing Activity | -0.18 | -1.86 | -2.38 | 25.37 |
| Net Cash Flow | 0.03 | 13.84 | -10.82 | 5.88 |
| Free Cash Flow | 0.28 | 2.87 | -8.64 | -9.46 |
| CFO/OP | 38 | 60 | -80 | -128 |

### Ratios

| Item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- |
| Debtor Days | 62.44 | 68.56 | 74.19 | 114.52 |
| Inventory Days | 30.97 | 28.85 | 42.6 | 46.48 |
| Days Payable | 15.44 | 5.13 | 7.71 | 31.77 |
| Cash Conversion Cycle | 77.96 | 92.29 | 109.07 | 129.23 |
| Working Capital Days | -83.94 | -60.1 | 58.73 | 64.69 |
| ROCE % | — | 14.75 | 20.4 | 11.59 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2025 | Mar 2026 |
| --- | --- | --- |
| Promoters | 78.3% | 56.43% |
| FIIs | 0% | 0% |
| DIIs | 0% | 0% |
| Government | 0% | 0% |
| Public | 20.5% | 39.78% |
| Others | 1.2% | 3.79% |
| No. of Shareholders | 46 | 380 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Buy
- **Buy / Neutral / Sell:** 7 / 6 / 6

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 66.18 | Sell |
| EMA (10) | 64.88 | Buy |
| SMA (20) | 63.85 | Buy |
| EMA (20) | 64.86 | Buy |
| SMA (50) | 65.97 | Sell |
| EMA (50) | 67.52 | Sell |
| SMA (100) | 77.81 | Sell |
| EMA (100) | 69.47 | Sell |
| SMA (200) | 66.02 | Sell |
| EMA (200) | 63.73 | Buy |

### Oscillators — summary: **Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 49.68 | Neutral |
| MACD (12,26,9) | -0.24 | Buy |
| Stochastic (14,3,3) | 42.16 | Neutral |
| ADX (14) | 25.78 | Buy |
| Williams %R (14) | -50.34 | Neutral |
| ATR (14) | 3.68 | High Volatility |
| ROC (12) | 1.72 | Buy |
| Stoch RSI (14) | 33.73 | Neutral |
| UO (7,14,28) | 45.95 | Neutral |

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 8 April 2026 - Vijaypd Ceutical approved 100% acquisition of Siddharth Drugs for Rs 7.01 crore, completion by 14 April 2026. | [Acquisition 8 April 2026 - Vijaypd Ceutical approved 100% acquisition of Siddharth Drugs for Rs 7.01 crore, completion by 14 April 2026.](https://nsearchives.nseindia.com/corporate/VIJAYPD_08042026194059_Reg_30_Outcome_of_Board_Meeting.pdf) |
| 6 Sep - AGM notice published; 42nd AGM on 28 September 2026, e-voting 25-27 September, book closure 23-29 September. | [Copy of Newspaper Publication 6 Sep - AGM notice published; 42nd AGM on 28 September 2026, e-voting 25-27 September, book closure 23-29 September.](https://nsearchives.nseindia.com/corporate/VIJAYPD_06092026224800_News_paper_NSE.pdf) |
| 5 May 2026 - Promoter confirms no share encumbrance during FY ended 31 March 2026. | [Disclosure under SEBI Takeover Regulations 5 May 2026 - Promoter confirms no share encumbrance during FY ended 31 March 2026.](https://nsearchives.nseindia.com/corporate/team_sandeshc_16042026113846_reg8.pdf) |
| 4 Sep - 2nd AGM on 30 Sep 2026; annual report filed, with related-party, loan and remuneration approvals proposed. | [Shareholders meeting 4 Sep - 2nd AGM on 30 Sep 2026; annual report filed, with related-party, loan and remuneration approvals proposed.](https://nsearchives.nseindia.com/corporate/VIJAYPD_04092026213136_Annual_Report_NSE.pdf) |
| 30 May 2026 - Audited FY26 results approved; profit ₹500.10 lakh; control acquired in Zen Pharmaceuticals from 1 Dec 2025. | [Outcome of Board Meeting 30 May 2026 - Audited FY26 results approved; profit ₹500.10 lakh; control acquired in Zen Pharmaceuticals from 1 Dec 2025.](https://nsearchives.nseindia.com/corporate/VIJAYPD_30052026215004_BM_Outcome_VijayPD_2026.pdf) |
| 30 April 2026 - Vijaypd Ceutical signed MoU with Ann Finechem LLP for ₹30.2 crore bulk API purchases over one year. | [Agreements 30 April 2026 - Vijaypd Ceutical signed MoU with Ann Finechem LLP for ₹30.2 crore bulk API purchases over one year.](https://nsearchives.nseindia.com/corporate/VIJAYPD_30042026105955_NSEannouncement30042026.pdf) |
| 3 Jul - Vijaypd Ceutical says corporate governance report not required for quarter ended 30 June 2026 under NSE EMERGE exemption. | [Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter 3 Jul - Vijaypd Ceutical says corporate governance report not required for quarter ended 30 June 2026 under NSE EMERGE exemption.](https://nsearchives.nseindia.com/corporate/VIJAYPD_03072026162900_Reg27Vijaypd30062026.pdf) |
| 3 Jul - Regulation 74(5) certificate for quarter ended 30 June 2026 filed. | [Certificate under SEBI (Depositories and Participants) Regulations, 2018 3 Jul - Regulation 74(5) certificate for quarter ended 30 June 2026 filed.](https://nsearchives.nseindia.com/corporate/VIJAYPD_03072026163409_Reg74_5_VIJAYPD_30062026.pdf) |
| 29 Aug - Board approved 2nd AGM notice, FY26 directors' report, cut-off date, and secretarial auditor appointment. | [Outcome of Board Meeting 29 Aug - Board approved 2nd AGM notice, FY26 directors' report, cut-off date, and secretarial auditor appointment.](https://nsearchives.nseindia.com/corporate/VIJAYPD_29082026131755_OutcomeofBM29082026.pdf) |
| 28 March 2026 - Trading window closed from April 1, 2026 until 48 hours after FY2026 audited results. | [Trading Window 28 March 2026 - Trading window closed from April 1, 2026 until 48 hours after FY2026 audited results.](https://nsearchives.nseindia.com/corporate/VIJAYPD_28032026130906_Trading_Window_March_2026.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Annual Report 2026 from nse](https://archives.nseindia.com/annual_reports/SME_AR_31459_VIJAYPD_2025_2026_A_3213829_04092026213557.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T20:37:33.300Z.